ArticleScientific reports2013
Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS.
Article in Scientific reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 56 citations in OpenAlex.
- The multifaceted roles of MCAM in development, homeostasis, pathological conditions, and cancer.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Galectin-3/CD146 interaction promotes renal damage and systemic inflammation after acute kidney injury.Scientific reports · 2025Article
- CD146, a therapeutic target involved in cell plasticity.Science China. Life sciences · 2024Review
- A subpopulation of CD146Cellular & molecular immunology · 2023Article
- CD146 expression profile in human skin and pre-vascularized dermo-epidermal skin substitutes in vivo.Journal of biological engineering · 2023Article
- Pro- and anti-tumour activities of CD146/MCAM in breast cancer result from its heterogeneous expression and association with epithelial to mesenchymal transition.Frontiers in cell and developmental biology · 2023Article
- CD146 as a promising therapeutic target for retinal and choroidal neovascularization diseases.Science China. Life sciences · 2022Article
- CD146 Associates with Gp130 to Control a Macrophage Pro-inflammatory Program That Regulates the Metabolic Response to Obesity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- CD146 bound to LCK promotes T cell receptor signaling and antitumor immune responses in mice.The Journal of clinical investigation · 2021Article
- Targeting the CD146/Galectin-9 axis protects the integrity of the blood-brain barrier in experimental cerebral malaria.Cellular & molecular immunology · 2021Article
- Phenotype and pathological significance of MCAMMolecular biology reports · 2021Article
- A large portion of the astrocyte proteome is dedicated to perivascular endfeet, including critical components of the electron transport chain.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- CD146/Soluble CD146 Pathway Is a Novel Biomarker of Angiogenesis and Inflammation in Proliferative Diabetic Retinopathy.Investigative ophthalmology & visual science · 2021Article
- Human Adipose Stem Cells (hASCs) Grown on Biodegradable Microcarriers in Serum- and Xeno-Free Medium Preserve Their Undifferentiated Status.Journal of functional biomaterials · 2021Article
- CD146 is a Novel ANGPTL2 Receptor that Promotes Obesity by Manipulating Lipid Metabolism and Energy Expenditure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Systemic Inflammation Index Values Are Associated With Worsened Disease Severity and Poor Response to Autoimmune Encephalitis Treatment.Frontiers in neurology · 2021Article
- CD146/sCD146 in the Pathogenesis and Monitoring of Angiogenic and Inflammatory Diseases.Biomedicines · 2020Review
- Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction.Theranostics · 2020Article
- MCAM/CD146 SignalingFrontiers in immunology · 2020Article
- CD146-HIF-1α hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to selectively block the entry of leukocytes into the central nervous system (CNS) without compromising the immune system is an attractive therapeutic approach for treating multiple sclerosis (MS). Using endothelial CD146-deficienct mice as a MS model, we found that endothelial CD146 plays an active role in the CNS-directed extravasation of encephalitogenic T cells, including CD146(+) TH1 and TH17 lymphocytes. Moreover, treating both active and passive MS models with the anti-CD146 antibody AA98 significantly decreased the infiltrated lymphocytes in the CNS and decreased neuroinflammation. Interestingly, the ability of AA98 to inhibit the migration of CD146(+) lymphocytes was dependent on targeting endothelial CD146, but not lymphocytic CD146. These results suggest a key molecular target located on the blood-brain barrier endothelium that mediates the extravasation of inflammatory cells into the CNS. In addition, our data suggest that the AA98 is a promising candidate for treating MS and other CNS autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.